Pages that link to "Q37268127"

The following pages link to Sorafenib and vorinostat kill colon cancer cells by CD95-dependent and -independent mechanisms (Q37268127):

Displaying 45 items.

• Ceramide synthases at the centre of sphingolipid metabolism and biology (Q24609859) (← links)
• Mammalian ceramide synthases (Q24633453) (← links)
• A critical role for ceramide synthase 2 in liver homeostasis: II. insights into molecular changes leading to hepatopathy (Q24634622) (← links)
• Modulation of Autophagy by Sorafenib: Effects on Treatment Response (Q26745320) (← links)
• c-FLIP, a master anti-apoptotic regulator (Q28391119) (← links)
• Sorafenib inhibits epithelial-mesenchymal transition through an epigenetic-based mechanism in human lung epithelial cells (Q28533484) (← links)
• Sorafenib and HDAC inhibitors synergize with TRAIL to kill tumor cells (Q33576187) (← links)
• Autophagy and cancer therapy (Q33584607) (← links)
• The pleiotropic roles of sphingolipid signaling in autophagy (Q33720239) (← links)
• Autophagic Mechanism in Anti-Cancer Immunity: Its Pros and Cons for Cancer Therapy (Q33839054) (← links)
• A natural BH3 mimetic induces autophagy in apoptosis-resistant prostate cancer via modulating Bcl-2-Beclin1 interaction at endoplasmic reticulum (Q34179998) (← links)
• Interdiction of sphingolipid metabolism to improve standard cancer therapies (Q34373466) (← links)
• Histone Deacetylase Inhibitors: Advancing Therapeutic Strategies in Hematological and Solid Malignancies (Q34399444) (← links)
• Bcl2L13 is a ceramide synthase inhibitor in glioblastoma (Q34413943) (← links)
• Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells (Q35113327) (← links)
• PHY906(KD018), an adjuvant based on a 1800-year-old Chinese medicine, enhanced the anti-tumor activity of Sorafenib by changing the tumor microenvironment (Q35227285) (← links)
• Targeting the Anti-Apoptotic Protein c-FLIP for Cancer Therapy (Q35762274) (← links)
• Expression of Ceramide Synthase 6 Transcriptionally Activates Acid Ceramidase in a c-Jun N-terminal Kinase (JNK)-dependent Manner (Q35860939) (← links)
• Combination of the deacetylase inhibitor panobinostat and the multi-kinase inhibitor sorafenib for the treatment of metastatic hepatocellular carcinoma - review of the underlying molecular mechanisms and first case report (Q35895346) (← links)
• Identification of initial leads directed at the calmodulin-binding region on the Src-SH2 domain that exhibit anti-proliferation activity against pancreatic cancer (Q35902399) (← links)
• Endogenous modulators and pharmacological inhibitors of histone deacetylases in cancer therapy (Q35975127) (← links)
• By activating Fas/ceramide synthase 6/p38 kinase in lipid rafts, stichoposide D inhibits growth of leukemia xenografts (Q36413845) (← links)
• Sorafenib and pemetrexed toxicity in cancer cells is mediated via SRC-ERK signaling (Q36919811) (← links)
• Synergistic antitumour activity of sorafenib in combination with tetrandrine is mediated by reactive oxygen species (ROS)/Akt signaling (Q37040669) (← links)
• Phase I study of pemetrexed with sorafenib in advanced solid tumors (Q37520649) (← links)
• Recently identified and potential targets for colon cancer treatment. (Q37763104) (← links)
• Autophagy and tumorigenesis (Q37768714) (← links)
• The neoadjuvant therapy of colorectal hepatic metastases and the role of biologic sensitizing and resistance factors (Q37821836) (← links)
• Targeting the growth factors and angiogenesis pathways: small molecules in solid tumors (Q37863629) (← links)
• Ceramide-orchestrated signalling in cancer cells. (Q38067062) (← links)
• Regulation of autophagy by kinases (Q38161364) (← links)
• PDE5 inhibitors enhance the lethality of [pemetrexed + sorafenib]. (Q38721255) (← links)
• Sorafenib reverses resistance of gastric cancer to treatment by cisplatin through down-regulating MDR1 expression (Q38921009) (← links)
• Combination of Vorinostat and caspase-8 inhibition exhibits high anti-tumoral activity on endometrial cancer cells. (Q39165456) (← links)
• Natural Bcl-2 inhibitor (-)- gossypol induces protective autophagy via reactive oxygen species-high mobility group box 1 pathway in Burkitt lymphoma (Q39196767) (← links)
• Perifosine and sorafenib combination induces mitochondrial cell death and antitumor effects in NOD/SCID mice with Hodgkin lymphoma cell line xenografts (Q39202496) (← links)
• Therapeutic implications of bioactive sphingolipids: A focus on colorectal cancer (Q39420607) (← links)
• Calmodulin mediates Fas-induced FADD-independent survival signaling in pancreatic cancer cells via activation of Src-extracellular signal-regulated kinase (ERK). (Q39536531) (← links)
• Vorinostat and sorafenib increase CD95 activation in gastrointestinal tumor cells through a Ca(2+)-de novo ceramide-PP2A-reactive oxygen species-dependent signaling pathway (Q39680200) (← links)
• OSU-03012 enhances Ad.7-induced GBM cell killing via ER stress and autophagy and by decreasing expression of mitochondrial protective proteins (Q39747108) (← links)
• Evaluation of metastatic and angiogenic potentials of human colon carcinoma cells in chick embryo model systems (Q39785586) (← links)
• NRAS mutations in cutaneous T cell lymphoma (CTCL) sensitize tumors towards treatment with the multikinase inhibitor Sorafenib (Q41233629) (← links)
• A phase I study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal cell carcinoma and non-small cell lung cancer (Q44442164) (← links)
• A novel role for ceramide synthase 6 in mouse and human alcoholic steatosis (Q47780310) (← links)
• Targeting sphingolipid metabolism as an approach for combination therapies in haematological malignancies (Q90651738) (← links)